Explore how Altasciences integrates pharmaceutical formulation development with nonclinical research to optimize drug formulations, assess risks, and support progression to FIH trials.

See how Altasciences’ integrated CDMO and nonclinical teams pivoted to capsule dosing to overcome formulation challenges, preserve a GLP study timeline, and avoid costly delays.

Understand how an integrated approach to first-in-human studies can support small and large molecule programs through efficient execution and informed development decisions.

Poor solubility can stand between a promising molecule and its potential. Discover how spray-dried dispersions can help move challenging compounds forward.

Discover how integrated formulation, manufacturing, and clinical strategies can accelerate early drug development, reduce timelines, and optimize drug products for clinical success.

Discover how our ClinDMO model transforms early drug development with on-demand manufacturing, adaptive formulation, and real-time decision-making to accelerate timelines and optimize API use.

Discover the power of discovery research, key trends shaping early-phase drug development, and two exclusive case studies from our Sacramento facility.

Understand how specialized assessments and early-phase clinical strategies can generate meaningful safety, pharmacology, and proof-of-concept data.

An integrated nanomilling and spray-drying approach reduces particle size, enhances stability, and transforms nanosuspensions into scalable solid forms—boosting dissolution, bioavailability, and therapeutic success.

Leverage our expertise in nanomilling and spray drying to address low solubility and improve the bioavailability and efficacy of challenging drug compounds.

Join Beatrice Setnik, PhD and Denise Milova, PhD, for a conversation on orexin rescheduling and the evolving regulatory landscape.

In this on-demand webinar, our manufacturing experts provide insights into the growing ophthalmic market and how to optimize your drug development research outcomes.

Traditional toxicity studies don’t always fit today’s complex drug modalities. Watch as experts discuss how we’re adapting small molecule IND-enabling studies to meet modern therapeutic challenges.

Check out this essential webinar, where our experts provide an in-depth review of gene therapy approaches in nonhuman primates.

Learn how to identify which cognitive and pharmacodynamic tests are required for novel CNS-active drugs and best practices on conducting them during First-In-Human (FIH) trials.

Check out our expert-led webinar on terminal sterilization vs. aseptic manufacturing, covering methods, regulatory expectations, and benefits for product safety, efficiency, and compliance.

Globally recognized consultants discuss how they are addressing the most pressing drug development topics in the ocular field.

Gain valuable insights into the cutting-edge approaches shaping the future of gene and cell therapy delivery, ensuring more effective and efficient translation from discovery to clinical application.

Looking to avoid unnecessary delays and costly rework? Check out this webinar that shares important considerations for embarking on a new drug development program. Watch now!

<p>Learn how CROs and CDMOs work in tandem to successfully address operational and regulatory challenges for pharmaceutical and biotech companies, and how this can determine study success or failure.</p>

Learn about key topics in nanomilling, including practical applications and advantages, specialized equipment, milling media, stabilizers, as well as manufacturing and scale-up considerations.

Discover the advantages of LFHCs, including improved solubility and bioavailability, enhanced stability, and customizable release profiles, and how they can accelerate drug development timelines.

Learn how CROs and CDMOs work in tandem to address operational and regulatory challenges for pharmaceutical and biotech companies, and how this can determine study success or failure.

Learn more about the benefits of nanomilling, types of milling media and stabilizers, and scale up for clinical manufacturing.